Shanghai Mianyi Biopharmaceutical

Mianyi Bio is a Shanghai-based biotechnology company specializing in the development of next-generation immunotherapies targeting intracellular antigens. The company leverages its proprietary TCR-like (TCRm) antibody platform to identify and develop antibodies that recognize peptide-MHC complexes, effectively allowing antibody-based therapies to target proteins previously only accessible to T-cells. Their pipeline focuses on high-value oncology targets such as NY-ESO-1, AFP, and GPC3 for the treatment of various solid tumors. Mianyi Bio aims to bridge the gap between the specificity of T-cell receptors and the versatility of antibody drug formats to address unmet needs in cancer treatment.